GlassScriptPhysician profile
Wei Mi
NPI 1871601401
$73,245.98
in general payments reported to CMS, 2019-2025
68 companies · $9,746 in 2025
The $9,746 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,491 · 2020: $17K · 2021: $17K · 2022: $11K · 2023: $5,848 · 2024: $8,085 · 2025: $9,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $7,785 · Consulting Fee: $150 · Education: $94.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,650.00 |
| Food and Beverage | $7,785.16 |
| Consulting Fee | $150.00 |
| Education | $94.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37,746.25 | 2019-2025 | |
| Allergan, INC. | $19,590.25 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $2,098.07 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,637.97 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Emd Serono, INC. | $889.65 | 2019-2025 | Mavenclad, Mavenclad |
| Amgen INC. | $799.84 | 2019-2024 | Uplizna |
| Eisai INC. | $796.78 | 2019-2025 | |
| Biogen, INC. | $638.64 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $524.51 | 2021 | |
| Lilly USA, LLC | $474.30 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Neurocrine Biosciences, INC. | $472.77 | 2019-2025 | |
| Sk Life Science, INC. | $459.88 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $443.55 | 2022-2025 | |
| Genentech USA, INC. | $430.49 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Ucb, INC. | $422.38 | 2020-2025 | Zilbrysq, Rystiggo |
Show all 67 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Mi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.